Skip to main content
. 2021 Sep 27;27(21):5857–5868. doi: 10.1158/1078-0432.CCR-19-2384

Figure 4.

Figure 4. End-of-treatment detectable HPV ctDNA is associated with disease recurrence. A, HPV ctDNA levels at the end-of-treatment timepoint obtained using HPV-seq are significantly higher among patients who subsequently relapsed (N = 4) versus patients who remained disease-free (N = 12). Horizontal bars indicate the median value and 1.5 times the interquartile range. B, PFS according to HPV ctDNA status at the end-of-treatment timepoint. Data represent HPV copies/mL plasma. Detectable HPV ctDNA, dashed red line. Undetectable HPV ctDNA, solid blue line. Vertical hash marks indicate censoring.

End-of-treatment detectable HPV ctDNA is associated with disease recurrence. A, HPV ctDNA levels at the end-of-treatment timepoint obtained using HPV-seq are significantly higher among patients who subsequently relapsed (N = 4) versus patients who remained disease-free (N = 12). Horizontal bars indicate the median value and 1.5 times the interquartile range. B, PFS according to HPV ctDNA status at the end-of-treatment timepoint. Data represent HPV copies/mL plasma. Detectable HPV ctDNA, dashed red line. Undetectable HPV ctDNA, solid blue line. Vertical hash marks indicate censoring.